Condition: Pseudomyxoma Peritonei · Colorectal Carcinoma · Ovarian Carcinoma · Sponsor: Oslo University Hospital
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
This description comes directly from the study's public registry record.
Kjersti Flatmark, MD PhD · +47 22 93 40 00 · Kjersti.Flatmark@rr-research.no
Annette Torgunrud Kristensen, PhD · +47 22 78 19 45 · atj@rr-research.no
Always discuss trial participation with your own doctor first.
| The Norwegian Radium Hospital | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02073500